Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 6 of 6 entries
Sorted by: Best Match Show Resources per page
Effects of Aging and Liver Disease upon the Pharmacokinetics of Nipradilol.

Clinical drug investigation

Aramaki T, Katsuta Y, Sekiyama T, Tsutsui H, Kome-Ichi H, Ohsuga M, Satomura K, Yoshimura M.
PMID: 18370546
Clin Drug Investig. 1998;16(3):251-7. doi: 10.2165/00044011-199816030-00009.

OBJECTIVE: The effects of aging and liver disease on the pharmacokinetics of nipradilol were studied after a single oral dose of 6mg.STUDY PARTICIPANTS: Nipradilol was administered to three groups of subjects: younger healthy volunteers with a mean age of...

Cite
Aramaki T, Katsuta Y, Sekiyama T, et al. Effects of Aging and Liver Disease upon the Pharmacokinetics of Nipradilol. Clin Drug Investig. 1998;16(3):251-7doi: 10.2165/00044011-199816030-00009.
Aramaki, T., Katsuta, Y., Sekiyama, T., Tsutsui, H., Kome-Ichi, H., Ohsuga, M., Satomura, K., & Yoshimura, M. (1998). Effects of Aging and Liver Disease upon the Pharmacokinetics of Nipradilol. Clinical drug investigation, 16(3), 251-7. https://doi.org/10.2165/00044011-199816030-00009
Aramaki, T, et al. "Effects of Aging and Liver Disease upon the Pharmacokinetics of Nipradilol." Clinical drug investigation vol. 16,3 (1998): 251-7. doi: https://doi.org/10.2165/00044011-199816030-00009
Aramaki T, Katsuta Y, Sekiyama T, Tsutsui H, Kome-Ichi H, Ohsuga M, Satomura K, Yoshimura M. Effects of Aging and Liver Disease upon the Pharmacokinetics of Nipradilol. Clin Drug Investig. 1998;16(3):251-7. doi: 10.2165/00044011-199816030-00009. PMID: 18370546.
Copy Download .nbib Format: NLM
Direct nitric oxide release from nipradilol in human coronary arterial smooth muscle cells observed with fluorescent NO probe and NO-electrode.

Pathophysiology : the official journal of the International Society for Pathophysiology

Ishida H, Hirota Y, Higashijima N, Ishiwata K, Chokoh G, Matsuyama S, Murakami E, Nakazawa H.
PMID: 15364117
Pathophysiology. 2004 Oct;11(2):77-80. doi: 10.1016/j.pathophys.2004.03.004.

BACKGROUND:: Nipradilol (3,4-dihydro-8-[2-hydroxy-3-isopropyl-amino]propoxy-3-nitroxy-2-H-1-benzopyran), a potent non-selective beta-adrenoceptor antagonist, has been shown to increase NO production. The mechanisms are up-regulation of nitric oxide synthase (NOS) and direct release of NO from nipradilol. The process of direct NO release from nipradilol...

Cite
Ishida H, Hirota Y, Higashijima N, et al. Direct nitric oxide release from nipradilol in human coronary arterial smooth muscle cells observed with fluorescent NO probe and NO-electrode. Pathophysiology. 2004;11(2):77-80doi: 10.1016/j.pathophys.2004.03.004.
Ishida, H., Hirota, Y., Higashijima, N., Ishiwata, K., Chokoh, G., Matsuyama, S., Murakami, E., & Nakazawa, H. (2004). Direct nitric oxide release from nipradilol in human coronary arterial smooth muscle cells observed with fluorescent NO probe and NO-electrode. Pathophysiology : the official journal of the International Society for Pathophysiology, 11(2), 77-80. https://doi.org/10.1016/j.pathophys.2004.03.004
Ishida, Hideyuki, et al. "Direct nitric oxide release from nipradilol in human coronary arterial smooth muscle cells observed with fluorescent NO probe and NO-electrode." Pathophysiology : the official journal of the International Society for Pathophysiology vol. 11,2 (2004): 77-80. doi: https://doi.org/10.1016/j.pathophys.2004.03.004
Ishida H, Hirota Y, Higashijima N, Ishiwata K, Chokoh G, Matsuyama S, Murakami E, Nakazawa H. Direct nitric oxide release from nipradilol in human coronary arterial smooth muscle cells observed with fluorescent NO probe and NO-electrode. Pathophysiology. 2004 Oct;11(2):77-80. doi: 10.1016/j.pathophys.2004.03.004. PMID: 15364117.
Copy Download .nbib Format: NLM
Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis.

Clinical ophthalmology (Auckland, N.Z.)

Kamiya K, Shimizu K.
PMID: 19668567
Clin Ophthalmol. 2009;3:211-3. doi: 10.2147/opth.s4914. Epub 2009 Jun 02.

We report on a patient in whom the use of antiglaucoma drugs has been beneficial for the attainment of monovision after laser in situ keratomileusis (LASIK). A 57-year-old woman undergoing LASIK complained of blurred vision in the right eye....

Cite
Kamiya K, Shimizu K. Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis. Clin Ophthalmol. 2009;3:211-3doi: 10.2147/opth.s4914.
Kamiya, K., & Shimizu, K. (2009). Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis. Clinical ophthalmology (Auckland, N.Z.), 3211-3. https://doi.org/10.2147/opth.s4914
Kamiya, Kazutaka, and Shimizu, Kimiya. "Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis." Clinical ophthalmology (Auckland, N.Z.) vol. 3 (2009): 211-3. doi: https://doi.org/10.2147/opth.s4914
Kamiya K, Shimizu K. Antiglaucoma drugs for achieving monovision after laser in situ keratomileusis. Clin Ophthalmol. 2009;3:211-3. doi: 10.2147/opth.s4914. Epub 2009 Jun 02. PMID: 19668567; PMCID: PMC2708990.
Copy Download .nbib Format: NLM
Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys.

Journal of ophthalmology

Kaneko Y, Ohta M, Isobe T, Nakamura Y, Mizuno K.
PMID: 28540083
J Ophthalmol. 2017;2017:7079645. doi: 10.1155/2017/7079645. Epub 2017 Apr 28.

Ripasudil hydrochloride hydrate (K-115), a specific Rho-associated coiled-coil containing protein kinase (ROCK) inhibitor, is developed for the treatment of glaucoma and ocular hypertension. Topical administration of ripasudil decreases intraocular pressure (IOP) by increasing conventional outflow through the trabeculae to...

Cite
Kaneko Y, Ohta M, Isobe T, et al. Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys. J Ophthalmol. 2017;2017:7079645doi: 10.1155/2017/7079645.
Kaneko, Y., Ohta, M., Isobe, T., Nakamura, Y., & Mizuno, K. (2017). Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys. Journal of ophthalmology, 20177079645. https://doi.org/10.1155/2017/7079645
Kaneko, Yoshio, et al. "Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys." Journal of ophthalmology vol. 2017 (2017): 7079645. doi: https://doi.org/10.1155/2017/7079645
Kaneko Y, Ohta M, Isobe T, Nakamura Y, Mizuno K. Additive Intraocular Pressure-Lowering Effects of Ripasudil with Glaucoma Therapeutic Agents in Rabbits and Monkeys. J Ophthalmol. 2017;2017:7079645. doi: 10.1155/2017/7079645. Epub 2017 Apr 28. PMID: 28540083; PMCID: PMC5429944.
Copy Download .nbib Format: NLM
Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma.

Clinical ophthalmology (Auckland, N.Z.)

Inoue K, Noguchi K, Wakakura M, Tomita G.
PMID: 21966188
Clin Ophthalmol. 2011;5:1211-6. doi: 10.2147/OPTH.S23233. Epub 2011 Aug 26.

BACKGROUND: The purpose of this study was to evaluate the effects of topical nipradilol monotherapy for 5 years on intraocular pressure, visual field performance, and optic disk topography.METHODS: Thirty patients with normal tension glaucoma were monitored for intraocular pressure...

Cite
Inoue K, Noguchi K, Wakakura M, et al. Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma. Clin Ophthalmol. 2011;5:1211-6doi: 10.2147/OPTH.S23233.
Inoue, K., Noguchi, K., Wakakura, M., & Tomita, G. (2011). Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma. Clinical ophthalmology (Auckland, N.Z.), 51211-6. https://doi.org/10.2147/OPTH.S23233
Inoue, Kenji, et al. "Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma." Clinical ophthalmology (Auckland, N.Z.) vol. 5 (2011): 1211-6. doi: https://doi.org/10.2147/OPTH.S23233
Inoue K, Noguchi K, Wakakura M, Tomita G. Effect of five years of treatment with nipradilol eye drops in patients with normal tension glaucoma. Clin Ophthalmol. 2011;5:1211-6. doi: 10.2147/OPTH.S23233. Epub 2011 Aug 26. PMID: 21966188; PMCID: PMC3180485.
Copy Download .nbib Format: NLM
Retrobulbar hemodynamic effects of nipradilol in normal and normal-tension glaucoma eyes.

Journal of ophthalmology

Fukukita M, Ido M, Osawa S, Sasoh M, Furuta M, Ito K, Sugimoto M, Uji Y.
PMID: 22132312
J Ophthalmol. 2011;2011:652904. doi: 10.1155/2011/652904. Epub 2011 Nov 03.

Purpose. To investigate the effects of nipradilol on retrobulbar hemodynamics. Methods. We investigated normal and normal-tension glaucoma (NTG) eyes. Topical nipradilol (one eye) and placebo eye drops (fellow eye) were instilled for 1 week in volunteers. Nipradilol was also...

Cite
Fukukita M, Ido M, Osawa S, et al. Retrobulbar hemodynamic effects of nipradilol in normal and normal-tension glaucoma eyes. J Ophthalmol. 2011;2011:652904doi: 10.1155/2011/652904.
Fukukita, M., Ido, M., Osawa, S., Sasoh, M., Furuta, M., Ito, K., Sugimoto, M., & Uji, Y. (2011). Retrobulbar hemodynamic effects of nipradilol in normal and normal-tension glaucoma eyes. Journal of ophthalmology, 2011652904. https://doi.org/10.1155/2011/652904
Fukukita, Mitsushi, et al. "Retrobulbar hemodynamic effects of nipradilol in normal and normal-tension glaucoma eyes." Journal of ophthalmology vol. 2011 (2011): 652904. doi: https://doi.org/10.1155/2011/652904
Fukukita M, Ido M, Osawa S, Sasoh M, Furuta M, Ito K, Sugimoto M, Uji Y. Retrobulbar hemodynamic effects of nipradilol in normal and normal-tension glaucoma eyes. J Ophthalmol. 2011;2011:652904. doi: 10.1155/2011/652904. Epub 2011 Nov 03. PMID: 22132312; PMCID: PMC3216384.
Copy Download .nbib Format: NLM
Showing 1 to 6 of 6 entries